Corvidia Therapeutics is a clinical-stage biotech based in Waltham, Massachusetts, focused on precision cardiovascular and cardio-renal therapies using functional genomics to identify patient subpopulations. Its pipeline includes an experimental therapy in Phase 2 for a genetically defined chronic kidney disease population and several preclinical cardiovascular programs. The company uses genetic variation studies to validate disease pathways and accelerate development for patients with unmet medical needs. Corvidia plans to use new funding to progress lead clinical programs, advance preclinical work, expand scientific and market access capabilities, and explore additional treatment areas. The company also intends to add new talent to support advancing programs and infrastructure. Recent executive leadership changes were announced alongside the financing to support the company’s growth and clinical goals. Corvidia Therapeutics focuses on developing precision cardiovascular therapies by leveraging functional genomics. The company’s lead therapeutic is COR-001, a licensed clinical-stage monoclonal antibody acquired from AstraZeneca. COR-001 was initially developed by MedImmune and previously entered a Phase 1 study for a different indication. Corvidia plans to use its new funding to progress COR-001 into Phase I/II clinical trials during 2016 and to advance its preclinical pipeline. The company was co-founded by CEO Michael Davidson, M.D., Rahul Kakkar, M.D., Matt Devalaraja, Ph.D., and Ram Aiyar, Ph.D., MBA. The financing strengthens the company’s balance sheet to support near-term clinical development activities.

Total raised

$86M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2018